MedPath

Comparison of efficacy of Teneligliptin and Sitagliptin for glucose fluctuation in Type 2 diabetes

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000022885
Lead Sponsor
niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients using oral diabetic therapy or insulin therapy, those with mild renal dysfunction (male:s-Cre>1.5, female:s-Cre>1.3), those with severe infectin, those with severe trauma and those with severe liver dysfunction (AST and ALT: 3 times the normal levels) were excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Maximum glucose level after supper
Secondary Outcome Measures
NameTimeMethod
AUC over 140 mg/dl after supper 18-24, AUC over 140 mg/dl after supper 20-24, GLP-1 level at 30 minutes after load, IRI level at 2h after load
© Copyright 2025. All Rights Reserved by MedPath